Attached files
file | filename |
---|---|
8-K - FORM 8-K - BAXANO SURGICAL, INC. | g21764e8vk.htm |
EX-99.1 - EX-99.1 - BAXANO SURGICAL, INC. | g21764exv99w1.htm |
EX-10.1 - EX-10.1 - BAXANO SURGICAL, INC. | g21764exv10w1.htm |
EX-99.2 - EX-99.2 - BAXANO SURGICAL, INC. | g21764exv99w2.htm |
Exhibit 99.3
TranS1 Inc. Announces Appointment of Ken Reali as President and Chief Operating Officer
WILMINGTON, NC, January 7, 2010 (GLOBE NEWSWIRE) TranS1 Inc. (Nasdaq:TSON), a medical device
company focused on designing, developing and marketing products that implement its proprietary
minimally invasive surgical approach to treat degenerative disc disease and instability affecting
the lower lumbar region of the spine, is pleased to announce the appointment of Ken Reali as
President and Chief Operating Officer.
We are excited to welcome Ken to the TranS1 team, said Richard Randall, CEO of TranS1. Kens
significant experience and proven track record in orthopedics, spine and biologics will be
invaluable as we continue to advance beyond our AxiaLIF minimally invasive approach to lumbar
fusion.
Mr. Reali has over 20 years of general management, sales and marketing experience with leading
medical device and orthopedic companies. He joins TranS1 from Smith & Nephew where he was most
recently Senior Vice President and General Manager of the Biologics and Spine Business. Prior to
Smith & Nephew, Mr. Reali held positions with Stryker and Biomet.
I am enthusiastic about the opportunity to join TranS1, commented Ken Reali, President and COO of
TranS1, I have had a chance to observe TranS1s products in the market and believe the minimally
invasive approach provides surgeons and patients with many unique advantages relative to other
lumbar fusion surgeries. I look forward to working with the Trans1 team to continue to expand its
market presence in spinal implants
About TranS1 Inc.
TranS1 is a medical device company focused on designing, developing and marketing products that
implement its proprietary minimally invasive surgical approach to treat degenerative disc disease
and instability affecting the lower lumbar region of the spine. TranS1 currently markets two
single-level fusion products, the AxiaLIF® and the AxiaLIF 360, and a two-level fusion product,
the AxiaLIF 2L, in the US and Europe. TranS1 was founded in May 2000 and is headquartered in
Wilmington, North Carolina. For more information, visit www.trans1.com.
Forward-Looking Statements
This press release includes forward-looking statements, the accuracy of which is necessarily
subject to risks and uncertainties. These risks and uncertainties include, among other things,
risks associated with the adoption of a new technology by spine surgeons, product development
efforts, regulatory requirements, maintenance and
prosecution of adequate intellectual property protection and other economic and competitive
factors. These forward looking statements are based on the companys expectations as of the date
of this press release and the company undertakes no obligation to update information provided in
this press release. For a discussion of risks and uncertainties associated with TranS1s business,
please review the companys filings with the Securities and Exchange Commission, including its
Annual Report on Form 10-K for the year ended December 31, 2008.
CONTACT:
Investors:
TranS1 Inc.
Michael Luetkemeyer, 910-332-1700
Chief Financial Officer
TranS1 Inc.
Michael Luetkemeyer, 910-332-1700
Chief Financial Officer
or
Westwicke Partners
Mark Klausner, 443-213-0501
mark.klausner@westwicke.com
Mark Klausner, 443-213-0501
mark.klausner@westwicke.com
Source: TranS1 Inc.